Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/srep11295.pdf
Reference49 articles.
1. Howlader, N. et al. (eds). SEER Cancer Statistics Review, 1975–2008. http://seer.cancer.gov/csr/1975_2008/ (2011).
2. Yin, J. A. et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120, 2826–2835, 10.1182/blood-2012-06-435669 (2012).
3. Loken, M. R. et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood 120, 1581–1588, 10.1182/blood-2012-02-408336 (2012).
4. Buonamici, S. et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 99, 443–449 (2002).
5. Dohner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453–474, 10.1182/blood-2009-07-235358 (2010).
Cited by 190 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Exosomes in liquid biopsy and oncology: Nanotechnological interplay and the quest to overcome cancer drug resistance;The Journal of Liquid Biopsy;2024-03
2. EV-mediated intercellular communication in AML: Transport of genetic materials in the bone marrow microenvironment;Experimental Hematology;2024-02
3. Adipose-derived extracellular vesicles – a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome;Endocrine;2024-01-29
4. A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia;Medical Oncology;2024-01-23
5. Utilizing exosomes as sparking clinical biomarkers and therapeutic response in acute myeloid leukemia;Frontiers in Immunology;2024-01-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3